TREATMENT OF AMERICAN TEGUMENTARY LEISHMANIOSIS WITH FLUCONAZOLE: CASE REPORT

Authors

  • Kauane Mayra de Oliveira Xavier Universidade Federal do Ceará
  • Rainardo Antônio Puster Hospital Universitário Walter Cantídio da UFC
  • Hermes Melo Teixeira Batista Faculdade de Medicina de Araripina FAP
  • Jorge Luiz Nobre Rodrigues Hospital Universitário Walter Cantídio da UFC

DOI:

https://doi.org/10.14295/aimj.v5i9.149

Abstract

Abstract: Leishmaniasis are diseases caused by protozoan parasites of the Leishmania genus, seen as a major public and social health problem, they represent a complex of diseases with different clinical presentations. Pentavalent antimonial drugs are the first choice in their treatment, however, this medications have disadvantages, such as the application and risks attributed to the toxicity. In this context, therapeutic options that present a suitable intake and satisfactory results are studied. The authors present a clinical case of American cutaneous leishmaniasis in a male patient, 89 years old, with cutaneous lesions on the nasal dorsum and on the left infraorbital margin, after the diagnosis, therapy with oral fluconazole was started, thus improving the disease. Oral triazole antifungals are a controversial topic in cutaneous leishmaniasis, even so, the use of oral fluconazole can be considered in patients with skin lesions, especially in patients susceptible to the greater possibility of complications due to side effects of pentavalent antimonial drugs.                   

 

Keywords: American Cutaneous Leishmaniasis. Fluconazole. Public health.

Author Biographies

Kauane Mayra de Oliveira Xavier, Universidade Federal do Ceará

1 Médica residente do programa de Clínica Médica pela Universidade Federal do Ceará – Hospital Universitário Walter Cantídio (HUWC). E-mail: kauanexavier@yahoo.com.br.

Rainardo Antônio Puster, Hospital Universitário Walter Cantídio da UFC

2 Orientador. Preceptor e vice-supervisor do Programa de Clínica Médica do Hospital Universitário Walter Cantídio da UFC. E-mail: rainardopuster@gmail.com;

Hermes Melo Teixeira Batista, Faculdade de Medicina de Araripina FAP

3 Doutor em Ciências da Saúde pela FMABC. Professor da Faculdade de Medicina de Araripina FAP;

Jorge Luiz Nobre Rodrigues, Hospital Universitário Walter Cantídio da UFC

4 Doutor em Doenças Infecciosas e Parasitárias pela Escola Paulista de Medicina. Preceptor do Programa de Infectologia do Hospital Universitário Walter Cantídio da UFC. E-mail: jorge1207@gmail.com.

 

References

Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Manual de vigilância da leishmaniose tegumentar. [Internet]. Brasília; 2017 [acesso em: 06 nov. 2018]. Disponível em http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_leishmaniose_tegumentar.pdf

Díaz SJ, Barrientos SS, Morell MS. Leishmaniasis cutánea. FMC - Formación Médica Continuada en Atención Primaria. 2012;19(3):117-28.

Guimarães LH, Machado PR, Lessa LH, Lessa M, D’Oliveira AJ, Carvalho EM. Aspectos Clínicos da Leishmaniose Tegumentar. Gazeta Médica Bahia, 2005; 75(1):66-74.

Handler M, Patel P, Kapila R, Al-Qubati Y, Schwartz R. Cutaneous and mucocutaneous leishmaniasis. Journal of the American Academy of Dermatology. 2015;73(6):911-26.

Herwaldt B. Leishmaniasis. The Lancet. 1999;354(9185):1191-99.

Sousa A, Frutuoso M, Moraes E, Pearson R, Pompeu M. High-Dose Oral Fluconazole Therapy Effective for Cutaneous Leishmaniasis Due to Leishmania (Vianna) braziliensis. Clinical Infectious Diseases. 2011;53(7):693-95.

Bailey M, Lockwood D. Cutaneous leishmaniasis. Clinics in Dermatology. 2007;25(2):203-11.

Cunha JCL, Cardoso ARP, Feijão LX, Crisóstomo BS, Oliveira RP. Aspectos clínicos e epidemiológicos da leishmaniose tegumentar americana no estado do Ceará, Brasil, no período de 2007 a 2016. Cadernos ESP, Ceará. 2017; 11 (2):10-17.

Kopterides P, Mourtzoukou E, Skopelitis E, Tsavaris N, Falagas M. Aspects of the association between leishmaniasis and malignant disorders. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101(12):1181-89.

Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H. Old World cutaneous leishmaniasis: diagnosis and treatment. Journal of Dermatological Case Reports. 2013; 7(2): 31-41.

Duarte M, Rochael M. Perfil histopatológico e imuno-histoquímico da leishmaniose tegumentar americana com ênfase nos dendrócitos dérmicos FXIIIa+. Anais Brasileiros de Dermatologia. 2006;81(6):541-48.

Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. The Lancet Infectious Diseases. 2007;7(9):581-96.

Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Medicine and Infectious Disease. 2007;5(3):150-58.

Beach D, Goad L, Holz G. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Molecular and Biochemical Parasitology. 1988;31(2):149-62.

Alrajhi A, Ibrahim E, De Vol E, Khairat M, Faris R, Maguire J. Fluconazole for the Treatment of Cutaneous Leishmaniasis Caused by Leishmania major. New England Journal of Medicine. 2002;346(12):891-95.

Published

2020-07-27

How to Cite

Xavier, K. M. de O., Puster, R. A., Batista, H. M. T., & Rodrigues, J. L. N. (2020). TREATMENT OF AMERICAN TEGUMENTARY LEISHMANIOSIS WITH FLUCONAZOLE: CASE REPORT. Amadeus International Multidisciplinary Journal, 5(9), 294–301. https://doi.org/10.14295/aimj.v5i9.149

Issue

Section

Case Report